There is increasing appreciation for the role of the neurovascular unit in neurodegenerative diseases. We showed previously that the angiogenic and neurotrophic cytokine, vascular endothelial growth factor (VEGF), is suppressed to abnormally low levels in spinocerebellar ataxia type 1 (SCA1), and that replenishing VEGF reverses the cerebellar pathology in SCA1 mice. In that study, however, we used a recombinant VEGF, which is extremely costly to manufacture and biologically unstable as well as immunogenic. To develop a more viable therapy, here we test a synthetic VEGF peptide amphiphile that self-assembles into nanoparticles. We show that this nano-VEGF has potent neurotrophic and angiogenic properties, is well-tolerated, and leads to functional improvement in SCA1 mice even when administered at advanced stages of the disease. This approach can be generalized to other neurotrophic factors or molecules that act in a paracrine manner, offering a novel therapeutic strategy for neurodegenerative conditions.
Introduction
The leading neurodegenerative diseases-Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, Huntington's disease and other polyglutaminopathies-are clinically and aetiologically heterogeneous. Yet it is increasingly apparent that these diseases, long considered strictly in terms of neuronal dysfunction, also disrupt the close coupling of neural activity with blood flow (Iadecola, 2017) . Several years ago, we discovered that the angiogenic and neurotrophic factor, VEGF (vascular endothelial growth factor) (Jin et al., 2002; Holmes and Zachary, 2005) , is downregulated in the polyglutamine disease spinocerebellar ataxia type 1 (SCA1); in fact, the protein ataxin-1 directly represses VEGF expression, and polyglutamine-expanded ataxin 1 (encoded by ATNX1) represses VEGF even more strongly (Cvetanovic et al., 2011) . SCA1 mice have low levels of VEGF in the cerebellum, the part of the brain most vulnerable to the disease, and they show deficits in the cerebellar vasculature and dendritic arborization. We then demonstrated that genetically or chemically replenishing VEGF mitigates the ataxia and dendritic defects of the SCA1 mice, raising the tantalizing possibility that SCA1 patients might benefit from VEGF treatment (Cvetanovic et al., 2011) . More recent studies in related proteopathies indicate that VEGF may also be therapeutic in Parkinson's disease (Caballero et al., 2017; Zou et al., 2017 ), Alzheimer's disease (Echeverria et al., 2017) , and amyotrophic lateral sclerosis (Wang et al., 2016) .
Unfortunately, significant impediments prevent the translation of recombinant VEGF therapy to the clinic. Not only is it extremely costly to manufacture, but it is biologically unstable (prone to proteolysis) and has a half-life of only $30 min in vivo (Thorne and Frey, 2001; Storkebaum et al., 2005) . It is also immunogenic, with antibodies directed against different epitopes interfering with its effects. We therefore sought to test a completely synthetic VEGF mimetic peptide in which a 15-amino acid VEGF sequence (KLTWQELYQLKYKGI) is covalently linked to an amphiphilic peptide (Webber et al., 2011) . These amino acids mimic VEGF residues 17 through 25 in their ability to bind and activate VEGF receptors (D'Andrea et al., 2005; Webber et al., 2011) . In the aqueous tissue environment, the peptide backbone promotes intermolecular b-sheet hydrogen bonding, leading to self-assembly of the VEGF peptide molecules into cylindrical nanostructures that express VEGF-mimetic epitopes on the surface at a high van der Waal density ($10 15 /cm 2 ). The VEGF-mimetic peptide amphiphile (VEGF-PA, henceforth called nano-VEGF) engages with VEGF receptors to result in potent signalling and is designed to eventually biodegrade. This peptide had been previously tested in a mouse hind-limb ischaemia model, which demonstrated that the particles are retained in tissue even 4 weeks after delivery (Webber et al., 2011) before slowly breaking apart (Silva et al., 2004; Webber et al., 2011) . Nano-VEGF had never been tested in the brain, but the small cross-section of the nanofibres ($10 nm diameter) would allow the particles to permeate the brain parenchyma. Here we tested the efficacy of nano-VEGF in preclinical studies in SCA1 mice.
Materials and methods

Human brain immunohistochemistry
SCA1 patient (n = 5) and age-matched (between the ages of 30 and 55 years) healthy control cerebella (n = 4) were provided as paraffin blocks by Dr Arnulf Koeppen (Albany Medical College, NY) (Edamakanti et al., 2018) . The Pathology Core Facility at Northwestern University performed immunohistochemistry for VEGF (Anti-VEGF ab39250; Abcam 1:100) on 5-mm thick human cerebellar tissues. Optical density analysis was carried out with background subtraction using ImageJ using colour deconvolution method as described previously (Ruifrok and Johnston, 2001 ).
Mouse lines
SCA1
154Q/2Q knock-in mice were generated as described (Watase et al., 2002) . These mice express a pathogenic polyglutamine tract of 154 repeats from one allele; the other allele expresses a normal mouse Atxn1 with two repeats (normal human alleles range from 6 to 44 polyglutamine repeats) (Quan et al., 1995; Servadio et al., 1995; Goldfarb et al., 1996) . Initially generated on a C57BL/6J-129SvEv mixed genetic background, the mice were backcrossed more than 10 generations with C57BL/6J mice to eliminate any background effects. Animal experiments were performed in compliance with National Institutes of Health's Guide for the Care and Use of Laboratory Animals and the Northwestern University Institutional Animal Care and Use Committee. All experiments were performed by investigators blinded to treatment versus control using age-matched controls and littermates. Since the phenotype of SCA1 knock-in mice does not differ significantly between male and female mice (Watase et al., 2002; Cvetanovic et al., 2011; Fryer et al., 2011; Ruegsegger et al., 2016) , we did not separate mice by sex.
Nano-VEGF synthesis
Nano-VEGF was engineered by linking to the N terminus of a VEGF peptide (designed to mimic VEGF residues 17-25), a K 3 G sequence to promote solubility and a V 2 A 2 b-domain followed by a C 16 alkyl chain to promote self-assembly as published previously (Webber et al., 2011) . The peptides were synthesized using 9-fluorenyl methoxycarbonyl (Fmoc) solid-phase peptide synthesis with rink amide 4-methylbenzhydrylamine resin (EMD Millipore). The synthesis was performed on a Liberty automated microwave peptide synthesizer (CEM Corp) at Northwestern's Peptide Synthesis Core. Fmoc groups were removed with 30% 4-methylpiperidine and 0.1 M hydroxybenzotriazole (HOBt) in N,N-dimethylformamide (DMF) at 75 C for 3-4min for each amino acid or palmitic acid (4 equiv.). The peptides were coupled at 75 C for 5-10 min using 4 equiv. of O-benzotriazole-N,N,N 0 ,N 0 -tetramethyluronium hexafluorophosphate (HBTU), and 8 equiv. of N,N-diisopropylethylamine (DIEA). The newly synthesized amphiphilic peptides were cleaved from the resin with a 95:2.5:2.5 trifluoroacetic acid (TFA)/triisopropylsilane (TIPS)/water mixture for 3-4 h. Rotary evaporation and precipitation in cold diethyl ether yielded the crude peptide mixture. Crude peptides were purified by HPLC (high performance liquid chromatography) on a C18 Phenomenex Jupiter column in a water-acetonitrile gradient containing 0.1% v/v TFA. Pure fractions were collected and identified using ESI-MS (electrospray ionization mass spectrometry). The combined fractions were subjected to rotary evaporation to remove volatile solvents; they were then frozen and lyophilized to dryness. The purity of the final lyophilized solid was verified by liquid chromatography mass spectrometry (LC-MS).
Delivery of nano-VEGF and recombinant VEGF with experimental time course
To test for behavioural and pathological improvement, mice were treated for a 2-week period starting at 24 weeks. Nano-VEGF, mouse rVEGF (#493-MV-025, R&D systems) or artificial CSF (sham controls) were delivered using the intracerebroventricular route (into the right lateral ventricle with stereotaxic coordinates: A/P À0.5 mm, M/L À1.1 mm, D/V À2.5 mm) using osmotic ALZET pumps (#1002, Durect) (Cvetanovic et al., 2011) . Behavioural assays were performed at 26 weeks; while biochemical and histochemical analysis was performed at 27 weeks (after euthanasia). For electrophysiological experiments, we used 8-10-week-old mice for pump placement (with a similar 2-week treatment regimen) since it is difficult to generate good electrophysiological traces from older mice.
Behavioural analyses Rotating rod assay
Mice (26 weeks old; post-treatment) were placed on a rotating rod apparatus (Ugo Basile) that accelerates linearly from 4 to 40 rotations per minute over a 5-min period. Mice were subjected to four trials per day for four consecutive days, each trial lasting to a maximum of 10 min, with at least 10 min of rest between each trial. The average performances for each day were plotted, and statistical differences between the different groups were analysed using repeated measures two-way ANOVA (followed by Tukey's honest significant difference post hoc test for multiple comparisons). All statistical analyses here and elsewhere were performed using GraphPad Prism 6 software (GraphPad Software, La Jolla California, USA). Data were considered significant for P 5 0.05. Data are expressed as mean AE standard error of the mean (SEM).
Gait analysis
We placed these same mice on a transparent treadmill belt connected to a high-speed digital video camera (Digigaitß system, Mouse Specifics, Inc.). The speed of the treadmill was set to the minimum of 5 cm/s up to maximum tolerated speed (maximum 24 cm/s). The performance of mice on the treadmill at different speeds was recorded with digital video camera (Supplementary material).
Mouse immunohistochemistry
Mice (27 weeks old; post-treatment and post-behavioural analysis) were anaesthetized by isoflurane inhalation and were perfused with ice-cold PBS, followed by 4% paraformaldehyde in PBS (Israeli et al., 2016) . The brains were post-fixed in 4% paraformaldehyde for 24 h, followed by tissue saturation in 30% sucrose for 48-72 h. Frozen brain blocks were prepared in O.C.T. (optimum cutting temperature) freezing medium and sagittally sectioned at 50 mm thickness using a cryostat (Leica). Immunohistochemistry was performed as described previously (Venkatraman et al., 2014) . Briefly, brain tissues were blocked and permeabilized with 5% normal donkey serum in Tris-buffered saline (TBS) with 0.25% Triton TM X-100 (TBST) for 2 h at room temperature. Slices were then incubated with primary antibodies for 48-72 h at 4 C. After three washes in TBST, signals were detected using according secondary antibodies for 2 h at room temperature. Brain slices were counterstained with DAPI (Invitrogen) and mounted with PVA (polyvinyl alcohol) DABCO Õ mounting medium. We studied at least three mice per experimental group and performed analysis on three to five sections per mouse. Images were taken as z-stack images using the Leica TCS SP5 confocal microscope (Cvetanovic et al., 2011) . To observe the morphology of Purkinje cells, we performed calbindin staining using mouse antiCalbindin-D-28 K (C9848, Sigma, 1:2000). To quantify dendritic length, we traced the calbindin-stained Purkinje cells and measured the length of the Purkinje cell dendrites from the proximal end of the soma to the distal end of the dendrites (using ImageJ 1.46 r Software; NIH, Bethesda, MD, USA). The vascular network was visualized by staining for Collagen IV (rabbit anti-Collagen IV, ab19808, Abcam, 1:400). Average vessel length and branching index were plotted and analysed by assessing the variation in foreground and background pixel mass densities across images using the open source AngioTool software (http://angiotool.nci. nih.gov) as described previously (Zudaire et al., 2011) . Statistical differences for dendritic length and microvasculature parameters were compared using one-way ANOVA followed by Tukey's post hoc test.
To quantify the percentage of cells with ataxin 1 inclusions in the CA1 regions of the hippocampus, brain sections were stained for ataxin 1 (mouse anti-Ataxin-1 11NQ clone N76/3; NeuroMab, 1:1000) and counterstained with DAPI. The number of cells with ataxin-1 inclusions in each defined region of interest was normalized to the number of cells stained with DAPI only. Statistical analysis was performed using unpaired t-test. In all cases, the secondary antibodies were generated in donkey (donkey anti-mouse Alexa Fluor Õ 647 and donkey anti-rabbit Alexa Fluor Õ 488; both at a dilution of 1:500, Invitrogen).
Western blot analysis
Proteins were extracted from cerebellar tissues using radioimmunoprecipitation assay (RIPA) buffer [50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 10 mM NaF, 0.5% sodium deoxycholate, 1% Triton TM X-100, 0.1% SDS, protease inhibitors (Sigma)], and resolved on 7.5% SDS-PAGE gel. Densitometric analysis was performed using ImageJ 1.46 r software. The following primary antibodies were used: mouse anti-Ataxin-1 (11NQ clone N76/3; NeuroMab, 1:1000); rabbit anti-Claudin 5 (34-1600, Thermo Fisher Scientific 1:200); rabbit anti-Occludin (71-1500, Thermo Fisher Scientific, 1:200); mouse anti-ZO-1 (33-9100, Thermo Fisher Scientific, 1:100), and mouse anti-beta Actin (A2228, Sigma, 1:5000). The secondary antibodies used were anti-rabbit IgG (H + L) HRP (W4011, Promega, 1:5000) or anti-mouse IgG (H + L) HRP (W4021, Promega, 1:5000) secondary antibodies and visualized with ECL substrate (GE). Film densitometric analysis was evaluated using ImageJ 1.46 r software. Statistical differences were compared using one-way ANOVA followed by Tukey's post hoc test.
Phospho-VEGFR2 ELISA
Phospho-VEGFR2 ELISA was performed using PathScan Õ Phospho-VEGFR2 (Ty1175) Sandwich ELISA kit (#7335, Cell Signaling), according to manufacturer's instructions. Briefly, cerebellar lysates were prepared in 2 Â cell lysis buffer, and undiluted tissue lysates were incubated in 96-well plates coated with phospho-VEGFR2 primary antibody overnight at 4 C. Wells were washed several times, and detection antibody was added to the well and incubated for 1 h at 37 C and with HRP-conjugated secondary antibody for 30 min at 37 C. Signals were detected with 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) substrate and sulphuric acid were added to stop the reaction. Absorbance was read at 450 nm within 30 min after stopping the reaction.
Electrophysiological slice recordings
Mice were anaesthetized with isoflurane and killed by decapitation. The brains were removed from the skull and placed in warm (30-33 C) artificial CSF containing (in mM): 125 NaCl, 25 NaHCO 3 , 2.5 KCl, 1.25 NaH 2 PO 4 , 0.5 CaCl 2 , 7 MgCl 2 , 75 sucrose and 25 glucose, equilibrated with 95% O 2 and 5% CO 2 (pH 7.4). Para-sagittal cerebellar slices (300-mm thick) were cut using a vibratome (Leica VT1200) and stored in the same solution at 34 C for 15 min and then at 20-22 C until used (46 h). For electrophysiological recordings, the slices were transferred to a chamber bathed in physiological artificial CSF [in mM: 125 NaCl, 25 NaHCO 3 , 2.5 KCl, 1.25 NaH 2 PO 3 , 25 glucose, 2.0 CaCl 2 and 1 MgCl 2 , (equilibrated with 95% O 2 and 5% CO 2 )] at 30-32 C. Slices were visualized using an upright microscope (Scientifica) equipped with a 40 Â water-immersion objective (Olympus), oblique illumination, and video microscopy using a digital camera (Q-imaging). Pipettes for cell-attached recordings were pulled from borosilicate glass (Sutter) using a horizontal puller (P97, Sutter). Tip resistances in working solution ranged from 3 to 6 M when filled with physiological artificial CSF. Electrophysiological recordings were obtained using an Axopatch 200B amplifier, filtered at 20 KHz and acquired at 10 KHz. Data were obtained and visualized using pClamp9 software. Cells were recorded in the I-Clamp fast mode. For all recordings, fast synaptic transmission was blocked by 3 mM kynurenic acid (Sigma) and 0.1 mM picrotoxin (Abcam). Statistical analysis was performed using unpaired t-test.
Data availability
The raw data that support the findings of this study are available from the corresponding authors, upon request.
Results
Nano-VEGF improves motor coordination in SCA1 mice with advanced disease
Cerebella of SCA1 knock-in mice show lower VEGF expression than wild-type (Cvetanovic et al., 2011) . To establish whether these observations extend to human patients, we performed immunohistochemical analysis on post-mortem cerebella obtained from SCA1 patients and age-matched controls. VEGF staining is clearly reduced in the cerebellar lobules of SCA1 patients ( Supplementary Fig. 1A and B) .
To test the therapeutic benefits of nano-VEGF, we turned to SCA1 knock-in mice (SCA1
154Q/2Q
), which reproduce the human disease remarkably well. Born without symptoms, they develop an adult-onset motor incoordination (around 8 weeks of age) that is steadily progressive and readily quantifiable by the accelerating rotating rod test (Watase et al., 2002; Cvetanovic et al., 2011; Ruegsegger et al., 2016) . They also develop progressive Purkinje cell degeneration, and show diminished cerebellar vasculature and Purkinje cell dendritic arborization. Previously, we showed that recombinant VEGF, delivered over a 2-week period starting at 11 weeks of age, improves motor coordination and mitigates these pathological features (Cvetanovic et al., 2011) .
We decided to test nano-VEGF against recombinant VEGF (rVEGF) on SCA1 mice at 24 weeks of age, which corresponds to advanced disease in humans. Any improvement in these mice would be a more stringent test of efficacy, and we wished to anticipate future human clinical trials that often involve patients with more advanced disease. The compounds were delivered over a 2-week period, rVEGF at a dose of 2.5 mg (dissolved in 100 ml of artificial CSF) (Cvetanovic et al., 2011) , and nano-VEGF at a dose of 20 mg. The bioequivalence of nano-VEGF was determined to be approximately eight times that of rVEGF based on functional studies in a mouse hind-limb ischaemia model (Webber et al., 2011) . The effects of both forms of VEGF were then evaluated at the end of the delivery period by behavioural testing in the 26th week and neuropathological assessment in the 27th week (Fig. 1A) .
Rotarod analysis at 26 weeks showed that SCA1 mice treated with either rVEGF or nano-VEGF performed markedly better than control SCA1 mice treated with artificial CSF (P 5 0.005) (Fig. 1B ) Nano-VEGF tended to produce a greater improvement than rVEGF, although this did not achieve statistical significance. We also performed a gait analysis using a videotaped assessment of gait on a transparent treadmill. SCA1 mice were barely able to walk on the moving treadmill even at low speed (5 cm/s), but mice treated with nano-VEGF (or rVEGF) could walk and even run when the speed of the treadmill was increased to 17 cm/s (tested up to 24 cm/s) (Supplementary Videos 1A-D) .
We next stained cerebellar sections from SCA1 mice with calbindin, which specifically stains Purkinje cells and is a standard technique to assess Purkinje cell pathology in SCA1. Purkinje cells in treated SCA1 mice had longer dendrites than artificial CSF-treated controls (Fig. 1C and D) . Interestingly, VEGF treatment did not affect the motor performance of wild-type mice, but did lengthen Purkinje cell dendrites (Supplementary Fig. 2A and B) .
Nano-VEGF improves neuropathological measures in SCA1 mice with advanced disease
In the nervous system, the effects of VEGF are mediated primarily by the membrane-spanning VEGF receptor 2 (VEGFR2), a tyrosine kinase receptor formed from two monomers. When VEGF binds, the monomers dimerize to cause autophosphorylation of the intracellular tyrosine residues, which activates downstream signalling pathways that mediate its effects (Cross and Claesson-Welsh, 2001 ). ELISA showed a decrease in the level of VEGFR2 phosphorylation consistent with low levels of VEGF in SCA1 mice compared to controls. This reduction of VEGFR2 phosphorylation is rescued by both rVEGF and nano-VEGF treatment, indicating that nano-VEGF functionally engages VEGF receptors (Fig. 2A) . Consistent with the lack of effect on motor performance in wild-type mice, VEGF treatment did not upregulate phosphorylation of VEGFR2 in wild-type mice, suggesting that there is a ceiling effect and the brain has only so much capacity for VEGF signalling (Supplementary Fig. 2C ).
Low levels of VEGF in SCA1 mice are associated with a pathological reduction in the microvasculature in SCA1 cerebella by Day 30, the earliest time tested. This vessel reduction is quantifiable as a decrease in the length and branching of capillaries (Cvetanovic et al., 2011) . Mice Figure 1 Nano-VEGF significantly improves cerebellar motor phenotype in late symptomatic SCA1 mice with effects comparable to recombinant VEGF. (A) Timeline of treatment and subsequent behavioural and pathological analyses. (B) Nano-VEGF and rVEGF both improved rotarod performance of SCA1 mice at 26 weeks (compared to SCA1 mice treated with artificial CSF). Data represent mean AE SEM. Two-way ANOVA follow by Tukey's test. *P 5 0.05, ***P 5 0.005. (C) Nano-VEGF and rVEGF treatment significantly increase dendritic length and improve morphology of Purkinje cells in SCA1 mice as assayed by calbindin staining. Scale bar = 100 mm. This is quantified in D. (D) Data represent mean AE SEM. At least three mice at 27 weeks were analysed in each experimental group. Statistical analysis: one-way ANOVA followed by the Tukey's post hoc test. ***P 5 0.005, ****P 5 0.0001. Continued treated with nano-VEGF showed a greater improvement in vessel length and branching index than mice treated with rVEGF ( Fig. 2B-D) . Western blot studies showed that reduced levels of capillary proteins [the tight junction markers ZO-1, claudin-4, and occludin (Chiba et al., 2008; Zhong et al., 2008) ] in SCA1 mice are restored with VEGF replenishment, and again nano-VEGF was more effective than rVEGF (Fig. 2E-H) .
Since the toxicity in SCA1 is caused by accumulation of ataxin-1, we asked whether VEGF might exert some effect, perhaps indirect, on protein levels. We found no difference in ataxin-1 levels between SCA1 and wild-type mouse brains (Fig. 3A) . The western blot is shown at two different exposures: the short exposure reveals ataxin-1 2Q, while the long exposure also reveals Ataxin-1 154Q, which is poorly soluble and remains in aggregates. Finally, one of the hallmarks of SCA1 pathology is an aggregation of ataxin-1 into nuclear inclusions in relatively spared brain regions such as the hippocampus. We found that 27-weekold mice treated with VEGF show no reduction in the levels of inclusions (Fig. 3B and C) . These results suggest that VEGF does not exert its beneficial effects by improving ataxin 1 proteostasis.
Nano-VEGF treatment improves the firing of Purkinje neurons in mice with advanced SCA1
To study the physiological effects of VEGF treatment on Purkinje cells, which is difficult to do in older mice because of the poorer quality of slice cultures, we also treated a cohort of younger, SCA1 mice at 8 to 10 weeks of age with nano-VEGF before performing electrophysiology. Purkinje cells provide the only output of the cerebellar cortex and transmit the integrated activity of the cortex to the cerebellar nuclei. In SCA1 mice, Purkinje cells show less spontaneous firing not only because of their own pathology but also because of a decrease in climbing fibre excitatory postsynaptic currents (Dell'Orco et al., 2015; Ruegsegger et al., 2016) and an increase in GABAergic inhibition from basket cells (Edamakanti et al., 2018) . Nano-VEGF-treated mice showed significantly faster and more regular firing compared with non-treated SCA1 mice, in keeping with the behavioural improvement ( Fig. 4A-C) .
Nano-VEGF thus activates VEGF signalling receptors, improves pathology and enhances the motor ability of SCA1 mice. The disease-modifying effects are quite remarkable, given that we initiated a treatment regimen only after neurodegeneration was well established.
Discussion
In this study, we tested a completely synthetic nano-VEGF whose functional epitopes have been designed to mimic the N-terminal helical domain of VEGF (residues 17-25) (Webber et al., 2011) . Nano-VEGF potently activates the VEGF receptor (VEGFR2) and improved the SCA1 phenotype on both behavioural and pathological assays. In fact, nano-VEGF outperformed recombinant VEGF in several respects, such as improving the levels of capillary proteins and microvascular health. As a pharmacological agent, nano-VEGF has several advantages over recombinant VEGF. Full-length recombinant VEGF is difficult to synthesize because of the protein's complex structure: it is a glycoprotein formed from two 165-amino acid monomers that must be joined by three interconnected disulphide bridges in a cysteine knot motif. Generating functional VEGF from bacterial and other expression systems is not only costly but inefficient, with considerable variations from one batch to the next (Storkebaum et al., 2005) .
Beyond these practical limitations, recombinant VEGF has poor pharmacokinetics, with a short half-life (Thorne and Frey, 2001; Storkebaum et al., 2005) . Nano-VEGF, on the other hand, is stable (detectable in an ischaemic limb model up to 4 weeks post-injection) and forms small filamentous structures that break apart slowly, essentially acting as a slow release formulation. In addition, the polyvalent nature of VEGF mimetic peptides on the surface is thought to promote receptor dimerization and sustained activation (Webber et al., 2011) . These parameters, which could help explain why nano-VEGF performs so favourably, will have to be more extensively studied in the nervous system to determine its pharmacokinetics in the brain.
The VEGF peptide itself is designed to engage with VEGFR1 and 2 (Wiesmann et al., 1997; Diana et al., 2008) . While it is not the only region of VEGF that has been shown to activate these receptors, this peptide has been the best characterized in functional models. It is possible that the activity of the peptide can be further improved. For instance, there are two other domains (VEGF residues 61-66 and residues 79-93) that also engage VEGF receptors, and it is likely that novel chimeric peptides could be synthesized to improve the efficacy compared to the nano-VEGF generated here (De Rosa et al., 2016) .
We chose intracerebroventricular delivery of nano-VEGF to avoid systemic effects. [There is at least the theoretical Figure 2 Continued increases the level of junction proteins in these mice. Representative gel images were spliced vertically and horizontally to demonstrate the level of junction proteins in each treatment group (n = 1). Images of full-length blots are included in Supplementary Fig. 3 . (F-H) Quantifications of western blot expression level of ZO-1, claudin-5 and occludin normalized to actin level. All values are mean AE SEM, one-way ANOVA, followed by Tukey's post hoc test. *P 5 0.05, ** P 5 0.001. possibility of promoting tumorigenesis (Carmeliet, 2005) , hypotension (Yang et al., 2002) , or coagulation disorders (Verheul et al., 2010) ]. There are alternatives to intracerebroventricular delivery, such as intraparenchymal delivery, but this method is even more invasive and fraught with side-effects of localized high concentrations such as increased vascular permeability, haemorrhage, inflammation, and non-physiological kinetics (an initial peak dose with tapering effects). Since VEGF by intracerebroventricular delivery enters the CSF and bathes the brain, one can be agnostic as to which circuits and cell types are being targeted. Furthermore, several companies have developed FDA-approved battery-operated pumps that deliver drugs via a subcutaneously placed catheter into the CSF for long-term drug delivery, which would obviate repeated intraparenchymal injections (Bottros and Christo, 2014) .
VEGF levels are abnormally suppressed in several neurodegenerative diseases, including amyotrophic lateral sclerosis, spinobulbar muscular atrophy, Parkinson's, and Alzheimer's disease. Nano-VEGF could well exert therapeutic benefits in these diseases as well. More broadly, a nanotechnology-based approach is likely to be applicable for other bioactive proteins such as BDNF, GDNF, NGF, and IGF1, all of which have also been implicated in neurodegeneration. Our results suggest that the use of self-assembling nanoparticles could lead to novel and effective therapeutic strategies for a variety of neurodegenerative disorders. 
